Palbociclib (PD-0332991) HCl Licensed by Pfizer

Catalog No.S1116

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Palbociclib (PD-0332991) HCl Chemical Structure

Palbociclib (PD-0332991) HCl Chemical Structure
Molecular Weight: 483.99

Validation & Quality Control

6 customer reviews :

Quality Control & MSDS

Related Compound Libraries

CDK Inhibitors with Unique Features

  • Pan CDK Inhibitor

    BAY 1000394 Pan-CDK1/2/3/4/7/9 inhibitor, IC50=5-25 nM.

  • Most Potent CDK Inhibitor

    LY2835219 CDK4, IC50=2 nM; CDK6, IC50=10 nM.

  • CDK Inhibitor in Clinical Trial

    Dinaciclib (SCH727965) Phase III for Chronic Lymphocytic Leukemia (CLL).

  • Newest CDK Inhibitor

    NU6027 Potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with Ki of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.

Product Information

  • Compare CDK Inhibitors
    Compare CDK Products
  • Research Area
  • Inhibition Profile

Product Description

Biological Activity

Description Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
Targets CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
CDK2/CyclinE2 [1]
(Cell-free assay)

 View  More

IC50 9 nM 11 nM 15 nM >10 μM
In vitro PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
MOLM13MWjLbY5ie2ViQYPzZZk>MmTUNlQhcA>?MXLJcohq[mm2aX;uJI9nKEOGS{SgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDSZkBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMECyJO69VQ>?MojpNlQ3PDFzMEO=
COLO205MmmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmDtO|IhcA>?NFjy[lFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMEO2JO69VQ>?Ml\nNlQ3PDFzMEO=
U937NGOzV5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGjRRXc4OiCqMlW3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{\XO|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjF2IN88US=>MnGzNlQ3PDFzMEO=
MOLM13MnTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWHwZ3ZbPzJiaB?=M1zoe2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV;MUVE{KGOnbHzzJIhiemKxcnnu[{BHVFR|IFnUSEBufXSjboSgZZN{\XO|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjB7NjFOwG0>MUeyOFY1OTFyMx?=
MOLM13M{P2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUO3NkBpNVzwVIR5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEB{d3KjZnXubYIuemW|aYP0ZY51KGi3bXHuJG1QVE1zMzDj[YxteyCjc4Pld5Nm\CCjczDpcoNwenCxcnH0bY9vKG:oIGuzTH11cHmvaXTpcoUhcW62bzDEUmEhf2m2aDDJR|UxKG:oIECuNFk3KM7:TR?=NG\0blIzPDZ2MUGwNy=>
MDA-MB-435NXTNc5BbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUKyOEBpMX7JR|UxRTBwMU[g{txONUfLRWp5OTV6MEG4N|E>
K562NIftWJFEgXSxdH;4bYMhSXO|YYm=MlmzPVYhcA>?NG\1fo9FVVORNI\KNmdKSzVyPUKg{txOMXWyOFQyPzV4Nh?=
DU145M4XMbGN6fG:2b4jpZ{BCe3OjeR?=M4XrUFk3KGh?M4S0UGROW09?MoPsTWM2OD15LkWg{txOMViyOFQyPzV4Nh?=
MDA-MB-231Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmHaNUDPxE1?MkPMNlQhcA>?M4DEOWROW09?MlvYR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JGcyKHCqYYPlMVSyOFQyPzV4Nh?=
MCF7MlfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXTaUFk6OSEQvF2=MUSyOEBpMWfEUXNQNIHId3NE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzFicHjhd4U>MV:yOFQyPzV4Nh?=
MCF7M2O2[WtqdmG|ZTDBd5NigQ>?NHyxXIs2KM7:TR?=MlHUNlQhcA>?MUXEUXNQNWfk[3Y{UW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBETEt2L3P5Z4xqdkRzIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZicnX0bY5w[myjc4TvcYEheGixc4Doc5J6dGG2aX;uJIF1KFOncke4NC=>MojGNlQ1OTd3Nk[=
MDA-MB-231NV7uR5Z{U2mwYYPlJGF{e2G7MVK1JO69VQ>?M3jYVlI1KGh?MXTEUXNQM3jzUGlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgR2RMPC:leXPsbY5FOSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHKndHnuc4Jt[XO2b33hJJBpd3OyaH;yfYxifGmxbjDheEBU\XJ5OEC=Ml3qNlQ1OTd3Nk[=
MDA-MB-231MV;GeY5kfGmxbjDBd5NigQ>?M3PUe|EuOTBizszNM4rhfVI1KGh?M4PJfmROW09?M{WycYRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYOgZZN{\XO|ZXSgZZMhWEGUUDDjcIVifmGpZR?=Mn\sNlQ1OTd3Nk[=
MCF7MnPNSpVv[3Srb36gRZN{[Xl?M3HIXlEuOTBizszNMlP0NlQhcA>?MoHZSG1UVw>?MYXkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m|IHHzd4V{e2WmIHHzJHBCWlBiY3zlZZZi\2V?M{XH[FI1PDF5NU[2
MDA-MB-231NIWwdFhHfW6ldHnvckBCe3OjeR?=NGDhb4IxNjVvMTFOwG0>NELlSHc1QCCqMmHnSG1UVw>?NHnjN2pp[XNibn:gR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JJN2[i2JMTDwbIF{\Q>?NIrLRnAzPDRzN{W2Oi=>
MCF7MWHGeY5kfGmxbjDBd5NigQ>?NV:2To9vOC53LUGg{txOMXW0PEBpMVLEUXNQNV\0ZlVNcGG|IH7vJGNmdGxiY4njcIUh[XK{ZYP0JIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDheEB{fWJvR{GgdIhie2V?NIGxN24zPDRzN{W2Oi=>
697NHLQR4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTF2OD6zPEBvVQ>?M3S2bHNCVkeHUh?=
P12-ICHIKAWAMkTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVzJR|UxRTl4LkC0JI5OMkTlV2FPT0WU
NB69MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX;ObJBvUUN3ME2xOlEvQCCwTR?=Mn\GV2FPT0WU
EoL-1NILoSGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTF6Nz6yOkBvVQ>?NWXxelU5W0GQR1XS
BHT-101M1rXcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVLJR|UxRTF7OD6yOUBvVQ>?M4qzW3NCVkeHUh?=
SK-NEP-1MlTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTJ{MD6wNkBvVQ>?MnHCV2FPT0WU
MHH-NB-11MlnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV;JR|UxRTJ{MD6xPUBvVQ>?M3z1cHNCVkeHUh?=
AsPC-1M3jSeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVXyboVmUUN3ME2yOVIvPTNibl2=MlrSV2FPT0WU
ES1NEHpWIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXzJR|UxRTJ3Nj6yOUBvVQ>?M3nrb3NCVkeHUh?=
LAMA-84NYP3T2VnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIPU[I5KSzVyPUK1PE4yQSCwTR?=MYXTRW5ITVJ?
MOLT-16M4XVNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MljSTWM2OD1{NUiuOFkhdk1?MoHqV2FPT0WU
ES7NYXFTpd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYXJR|UxRTJ5Mz6wPUBvVQ>?M2nvN3NCVkeHUh?=
KY821MkLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWXJR|UxRTNzND6xJI5OMmHnV2FPT0WU
RT-112MnS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFHSXnRKSzVyPUOyNU4xPSCwTR?=MXzTRW5ITVJ?
HL-60NGL0O5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTN2MD62OkBvVQ>?MnrPV2FPT0WU
MOLT-4M4O4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4X3W2lEPTB;M{S1MlE{KG6PMUjTRW5ITVJ?
KARPAS-45NEjaZ5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoXVTWM2OD1|N{[uNVYhdk1?MUXTRW5ITVJ?
SK-N-ASNELLdYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTN6Nz64N{BvVQ>?MnTDV2FPT0WU
CTB-1NXHje5BLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUnDbnZyUUN3ME20NFUvODJibl2=MX7TRW5ITVJ?
NKM-1MmXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYHlU4Q2UUN3ME20NVEvQDlibl2=NWjXOGo3W0GQR1XS
HTC-C3M{jtSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml:wTWM2OD12M{KuPVUhdk1?NVPs[IkzW0GQR1XS
BE-13NH\YPXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2Sw[2lEPTB;NES0MlI4KG6PNV;NNW9ZW0GQR1XS
KOSC-2Mnq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGfsR4lKSzVyPUS2Ok46KG6PMn;vV2FPT0WU
NB14M4DvU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NImyUplKSzVyPUS4N{42QCCwTR?=MUjTRW5ITVJ?
CAL-27M3Gwdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2nHNGlEPTB;NEm0MlU6KG6PNID3bmVUSU6JRWK=
H9NFLXfpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlriTWM2OD12OUWuOFMhdk1?M{PESXNCVkeHUh?=
RS4-11NYfnW4JvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoDKTWM2OD13MESuO|Mhdk1?NH\Y[YVUSU6JRWK=
PA-1MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2qycmlEPTB;NUC5Mlg3KG6PMmfWV2FPT0WU
MV-4-11MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;VS2lEPTB;NUGzMlg2KG6PMVHTRW5ITVJ?
OS-RC-2MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljVTWM2OD13MkGuOlIhdk1?M4jrXXNCVkeHUh?=
RPMI-8226MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn3JTWM2OD13Mk[uPFYhdk1?NGTISmJUSU6JRWK=
HGC-27MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXzJR|UxRTV4ND65PUBvVQ>?MlrVV2FPT0WU
CHP-212MnL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV32T5ZbUUN3ME21PVMvPTlibl2=MoniV2FPT0WU
NB10NEmzR2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVvJR|UxRTV7OT6xPEBvVQ>?MmD0V2FPT0WU
HHNEDLOGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEX2V|VKSzVyPUW5PU41OyCwTR?=MWrTRW5ITVJ?
EW-16MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXvVTHk5UUN3ME22NFMvPTJibl2=Mlz5V2FPT0WU
ES8M{jnNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWGxUI46UUN3ME22NFUvOjFibl2=M1P4VnNCVkeHUh?=
HAL-01MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIfz[olKSzVyPU[wOU43PyCwTR?=MorRV2FPT0WU
A204MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlztTWM2OD14M{OuPVEhdk1?M{fUcHNCVkeHUh?=
MHH-PREB-1MlrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVzJR|UxRTZ|Nj65PUBvVQ>?MYXTRW5ITVJ?
EM-2MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MorKTWM2OD14NUCuOlQhdk1?Mn[xV2FPT0WU
BV-173M3n4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUC4Vm5lUUN3ME22OVIvPDhibl2=NV;sfZh3W0GQR1XS
ONS-76NWfPNJZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3nvbGlEPTB;Nke3MlgzKG6PNVi3bHdDW0GQR1XS
KM-H2NWH2fYdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2n0bWlEPTB;Nkm1MlU1KG6PM1O3NXNCVkeHUh?=
D-263MGNXzGNVNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MojMTWM2OD15MUeuNVIhdk1?MUHTRW5ITVJ?
ES3NYXHe|FwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3[yR2lEPTB;N{K4Mlk{KG6PNX\lXVM4W0GQR1XS
VA-ES-BJNIe1O2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTd|Mj6yO{BvVQ>?MnXSV2FPT0WU
NBsusSRNFXNNI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVL6fmhzUUN3ME23OFIvQTlibl2=NWLJemVVW0GQR1XS
NCI-H520NYXoZ2hHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1HTSWlEPTB;N{S2MlUzKG6PMkfYV2FPT0WU
ES5M2C4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHvwSmpKSzVyPUe1Nk45KG6PMXjTRW5ITVJ?
T-24NWrSdmRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYrJR|UxRTd5OD63NUBvVQ>?MWrTRW5ITVJ?
SW962M2fheWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MW\JR|UxRThyOD62N{BvVQ>?NIS3T5dUSU6JRWK=
EW-3MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml;qTWM2OD16MEiuO|Yhdk1?MV3TRW5ITVJ?
RXF393M1PXS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vneGlEPTB;OEGyMlc6KG6PMWfTRW5ITVJ?
U251MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVrR[5o4UUN3ME24NVMvQDhibl2=NVjIb4NEW0GQR1XS
CAMA-1M3HXPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUPvV2UzUUN3ME24N|MvQTRibl2=MVLTRW5ITVJ?
JVM-3M3nkeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHrqd3ZKSzVyPUi1NU44QCCwTR?=Mn3hV2FPT0WU
COLO-800MoTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3LBfmlEPTB;OEm3Mlc5KG6PMk\2V2FPT0WU
OVCAR-5NUjiZlQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2HIUWlEPTB;OUCwMlEhdk1?MmnPV2FPT0WU
LB1047-RCCMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4jtWmlEPTB;OUK3MlU3KG6PMULTRW5ITVJ?
SW954NWrENXNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRTl{OT60NUBvVQ>?MWjTRW5ITVJ?
J-RT3-T3-5M1TvXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWfJR|UxRTl|Nj6wOkBvVQ>?MX;TRW5ITVJ?
MewoMkX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFv0SHZKSzVyPUmzOk43KG6PNInjemVUSU6JRWK=
NCI-H1770NHLvOlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\zRmlEPTB;OUSwMlU2KG6PM2\RdXNCVkeHUh?=
HO-1-N-1NXvuR3lOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXThb2dDUUN3ME25OlIvQDFibl2=M3rqbXNCVkeHUh?=
HSC-3NXvZVZUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUPubXVrUUN3ME25OlYvPDhibl2=MWHTRW5ITVJ?
TYK-nuNHfBSG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVTOUGhjUUN3ME25PVgvOjVibl2=M4HJeHNCVkeHUh?=
KYSE-150MmrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIjZNolKSzVyPUGuNFAxPzZizszNMnTQV2FPT0WU
SN12CMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnvjTWM2OD1zLkCwPFc2KM7:TR?=NXzqVWFZW0GQR1XS
MOLT-13NIjKZo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUj3e|VGUUN3ME2xMlAyPDJzIN88US=>MnTLV2FPT0WU
TE-11NFzWTmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlvaTWM2OD1zLkC0PFEzKM7:TR?=MXXTRW5ITVJ?
DBNInMdplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIfa[ohKSzVyPUGuNFczPzNizszNMm\SV2FPT0WU
CAL-39M4PLU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIX3eYpKSzVyPUGuNFc2OjJizszNMljpV2FPT0WU
A3-KAWNV64OHB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmnrTWM2OD1zLkC4OFA5KM7:TR?=NU\Ye2xkW0GQR1XS
CHP-134MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFfLd4RKSzVyPUGuNVE5ODdizszNM{\adHNCVkeHUh?=
TGWMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlTZTWM2OD1zLkGyN|k2KM7:TR?=M1OzZ3NCVkeHUh?=
QIMR-WILMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnzKTWM2OD1zLkGzNVM1KM7:TR?=MlPGV2FPT0WU
NCI-SNU-1MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTFwMU[zOVQh|ryPNIrvSW9USU6JRWK=
CGTH-W-1MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MknnTWM2OD1zLkG3NVg3KM7:TR?=MUTTRW5ITVJ?
MHH-ES-1MlH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFzycoJKSzVyPUGuNVc6QDZizszNMlXVV2FPT0WU
LB2241-RCCNYXoSII6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmfUTWM2OD1zLkG4OlIh|ryPNH63UWlUSU6JRWK=
ML-2MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFPaOHFKSzVyPUGuNlA4OzRizszNMlzZV2FPT0WU
COR-L23NW\4cop7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{\Pc2lEPTB;MT6yNlk{OyEQvF2=NGjEenpUSU6JRWK=
BFTC-905Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4Xv[2lEPTB;MT6yOFI3PyEQvF2=NV63dY96W0GQR1XS
Hs-578-TM1jueGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVjnN21sUUN3ME2xMlI2QDF5IN88US=>NYH1T3BkW0GQR1XS
KG-1MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkjSTWM2OD1zLkK2Olg3KM7:TR?=MX7TRW5ITVJ?
HELMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHzVeYJKSzVyPUGuNlk{OzhizszNM1z5U3NCVkeHUh?=
A549NFrqSWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NW\RPJAyUUN3ME2xMlI6Ozl7IN88US=>NHnUPGlUSU6JRWK=
COLO-741NX;yTpJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYXnZ3VtUUN3ME2xMlMzODh7IN88US=>M4\lPXNCVkeHUh?=
PC-3NEDrRW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWPlSVM1UUN3ME2xMlM2OjJzIN88US=>NWjaSlNGW0GQR1XS
HOSNIPRdYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHH3dG1KSzVyPUGuN|UzQTZizszNMnzCV2FPT0WU
HT-1080M{DZWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWO3e3llUUN3ME2xMlM4PTF7IN88US=>MXLTRW5ITVJ?
TE-8M{fYbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M36weGlEPTB;MT60NVc4PCEQvF2=MkHIV2FPT0WU
BHYNUX5fYNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MorITWM2OD1zLkS2PVI{KM7:TR?=M3zyUXNCVkeHUh?=
BB65-RCCNWXx[IlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYDJR|UxRTFwNUC1Nlgh|ryPM{fDXnNCVkeHUh?=
HNMnTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYD3THNNUUN3ME2xMlU1ODdzIN88US=>NEHHZYtUSU6JRWK=
NCI-H441MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmXxTWM2OD1zLkW0PVA4KM7:TR?=MnLIV2FPT0WU
RPMI-8866M{W1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXTJR|UxRTFwNUi1NFch|ryPNV3RS2pNW0GQR1XS
CAL-62MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnfmTWM2OD1zLk[wPFYzKM7:TR?=NYnjWZZIW0GQR1XS
MG-63Mn\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXrPZoZPUUN3ME2xMlYyQDF|IN88US=>NXfydlVtW0GQR1XS
SK-LU-1M{T1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUnaclV3UUN3ME2xMlYzOTV{IN88US=>MYXTRW5ITVJ?
BCPAPMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4PudGlEPTB;MT62OlQ2PyEQvF2=NFzTe4dUSU6JRWK=
22RV1NV;zcnB6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4fOSWlEPTB;MT62O|g1OyEQvF2=MkTNV2FPT0WU
T47DM4\kNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NInsPHpKSzVyPUGuOlgxPjFizszNM{Dwc3NCVkeHUh?=
MSTO-211HNUDaZ3hRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2Dnc2lEPTB;MT62PVYxOyEQvF2=NVvoR4k2W0GQR1XS
DELMoO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2HmXmlEPTB;MT63NFI4OyEQvF2=MnrRV2FPT0WU
H4Mn3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWXFVWkyUUN3ME2xMlc{OjF{IN88US=>M2GwWHNCVkeHUh?=
CAL-51MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2\aXWlEPTB;MT63OFg2PSEQvF2=NGDIUGdUSU6JRWK=
ABC-1M{DxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoCwTWM2OD1zLke4OVgzKM7:TR?=MULTRW5ITVJ?
MZ2-MELNED1TJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkP1TWM2OD1zLke5OVQzKM7:TR?=NWTrU|dTW0GQR1XS
YKG-1MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTFwOEGwOlEh|ryPNEKxNlFUSU6JRWK=
KM12Mk\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkPzTWM2OD1zLkixOlAzKM7:TR?=M2nBcXNCVkeHUh?=
L-363MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkjzTWM2OD1zLki3OFEzKM7:TR?=NIftS3lUSU6JRWK=
KU812NETkcHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NELkSJZKSzVyPUGuPFkzQDJizszNMWfTRW5ITVJ?
LOXIMVIMnT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3zzXGlEPTB;MT65NVIzQCEQvF2=MmX2V2FPT0WU
G-401MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUHNZXZsUUN3ME2xMlkzPDJ6IN88US=>NXjPelZjW0GQR1XS
SW780NULnPFdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF;wdINKSzVyPUGuPVYzPDZizszNMYTTRW5ITVJ?
SW872MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{f4TGlEPTB;MT65PFM{KM7:TR?=MVjTRW5ITVJ?
NB7NF\OW5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFHnNZJKSzVyPUGuPVk{OjNizszNM1Lxe3NCVkeHUh?=
T98GNWnUPJNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NULDboxGUUN3ME2yMlAxPjZ4IN88US=>MlznV2FPT0WU
SW1710NXXYTlZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXzJR|UxRTJwME[5OFUh|ryPMVXTRW5ITVJ?
NCI-H1573Mn7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYjOO2xLUUN3ME2yMlA4Ojl6IN88US=>M3TJUnNCVkeHUh?=
KE-37MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3e3e2lEPTB;Mj6wPFk2OSEQvF2=M4Hle3NCVkeHUh?=
786-0MkexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2TvPWlEPTB;Mj6xOVQ{QSEQvF2=Ml\yV2FPT0WU
SASNUflU4pbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mkf5TWM2OD1{LkKwN|c1KM7:TR?=NX;pfVM3W0GQR1XS
CAL-54MmexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGG5RpBKSzVyPUKuNlA1OTNizszNNIDWS2FUSU6JRWK=
SF268M{OxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX;iRZpbUUN3ME2yMlI{OTJ{IN88US=>M{\PVnNCVkeHUh?=
SW620NVq1NJBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRTJwMk[xOlkh|ryPNEfFcGRUSU6JRWK=
MN-60MlK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVjUTlhkUUN3ME2yMlMyODZizszNM4jQPXNCVkeHUh?=
EFO-27NG\TZYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXvrTHhwUUN3ME2yMlMzODV6IN88US=>NFLJWXZUSU6JRWK=
NCI-H747M1v6NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4nqWWlEPTB;Mj6zNlE6QSEQvF2=MV7TRW5ITVJ?
HCC2218MnuwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnyyTWM2OD1{LkO1N|c1KM7:TR?=M1vWbXNCVkeHUh?=
MIA-PaCa-2MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTJwM{[0N|ch|ryPM1TuUXNCVkeHUh?=
SJSA-1NGPlOZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIq4eXRKSzVyPUKuN|c4QTZizszNNGLOUoZUSU6JRWK=
RKONFfpbXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnq5TWM2OD1{LkO4OFk3KM7:TR?=NHrqRnRUSU6JRWK=
NB6M2XYUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIXtO5NKSzVyPUKuOFA{PzRizszNM4nWTHNCVkeHUh?=
ES4MlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1q3c2lEPTB;Mj60OVQzOiEQvF2=MXfTRW5ITVJ?
EGI-1MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHntUFJKSzVyPUKuOFY5QDNizszNNUHsNmxSW0GQR1XS
CTV-1NUPxWHh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX7JR|UxRTJwNUK3O|Mh|ryPM4e4cHNCVkeHUh?=
NCI-H1355MknJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTJwNUW5OVEh|ryPM3fBcHNCVkeHUh?=
GT3TKBM2K0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIHEcnZKSzVyPUKuOVkyQTlizszNNXTKVGVjW0GQR1XS
SK-HEP-1NYfCUWp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2j4T2lEPTB;Mj61PVI3PiEQvF2=MXrTRW5ITVJ?
GAMGM{n6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MofDTWM2OD1{LkW5N|k1KM7:TR?=NXjFTY9tW0GQR1XS
SK-MES-1M{W5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWnldZFUUUN3ME2yMlYyQDB|IN88US=>MnGzV2FPT0WU
RO82-W-1Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIGyO3BKSzVyPUKuOlIxPTdizszNMVHTRW5ITVJ?
ECC10Mn3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlWzTWM2OD1{LkewNlA3KM7:TR?=NHXjSo5USU6JRWK=
MCF7NXq0e4VbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYnJR|UxRTJwN{G0OlQh|ryPMmXuV2FPT0WU
D-283MEDMlvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXXJR|UxRTJwN{K0N{DPxE1?M2exfXNCVkeHUh?=
RPMI-7951M33VVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmL2TWM2OD1{Lke1Olk1KM7:TR?=NYnNWlI5W0GQR1XS
Ramos-2G6-4C10NVPxXW9bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MknMTWM2OD1{Lke3NFk6KM7:TR?=NGjMe|RUSU6JRWK=
KGNMoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NILNbYVKSzVyPUKuPFE5QDRizszNNHHmUVNUSU6JRWK=
NUGC-3MmjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmXzTWM2OD1{LkiyOVA2KM7:TR?=MV\TRW5ITVJ?
NCI-H292NFW4dXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVH0[pRWUUN3ME2yMlg2ODV|IN88US=>MWnTRW5ITVJ?
BeckerMmHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmfRTWM2OD1{Lkm1PFMzKM7:TR?=MYnTRW5ITVJ?
NCI-H1299NWPt[3ZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2LyW2lEPTB;Mz6wOVI3OyEQvF2=NHrhWY9USU6JRWK=
ETK-1NFXNRpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTNwMEW0N{DPxE1?MUPTRW5ITVJ?
TK10MlLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXzzOGVuUUN3ME2zMlIxOTZ3IN88US=>NHO3b3ZUSU6JRWK=
VMRC-RCZNIPGUZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWTYNpg2UUN3ME2zMlM3PDh6IN88US=>NHHqe25USU6JRWK=
YH-13M{i4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3XiRWlEPTB;Mz60OFA4QSEQvF2=M3O2RnNCVkeHUh?=
DU-145M3\kUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmjrTWM2OD1|LkS2NlY6KM7:TR?=MmHIV2FPT0WU
SW1088MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWS4SohzUUN3ME2zMlQ4PDdizszNMkfFV2FPT0WU
HOP-92MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NI\FcWJKSzVyPUOuOVA{PDJizszNNVHETlFPW0GQR1XS
KP-N-YSMnrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUXPNlNKUUN3ME2zMlYzOTN7IN88US=>MWXTRW5ITVJ?
NCI-H460M2DCR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVvJR|UxRTNwNk[3N{DPxE1?NV71VllkW0GQR1XS
U-2-OSMl\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTNwN{K1N|Uh|ryPMVPTRW5ITVJ?
A101DNF3VSXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUTqSpZuUUN3ME2zMlc3QTN4IN88US=>MnLCV2FPT0WU
MDA-MB-231NV:5WWtbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MliyTWM2OD1|LkixPVUyKM7:TR?=MXLTRW5ITVJ?
IST-MES1M3SwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTNwOEOyJO69VQ>?NXvkOXVoW0GQR1XS
COR-L105MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYLWXmVnUUN3ME20MlAyQCEQvF2=M3u0dHNCVkeHUh?=
NCI-H1437M{X2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWHTZ|ZYUUN3ME20MlAzOzB{IN88US=>MX;TRW5ITVJ?
CAL-85-1M2L4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1LxNmlEPTB;ND6wNlQ3OSEQvF2=NWqwRVJuW0GQR1XS
MZ1-PCMkTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLJR|UxRTRwMUi1OVYh|ryPMmfuV2FPT0WU
VM-CUB-1M3nycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4j2TGlEPTB;ND6zNVI5PCEQvF2=M2HpeXNCVkeHUh?=
CHL-1NX61SldnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MknuTWM2OD12LkOyNVY6KM7:TR?=NV62eHJiW0GQR1XS
MDA-MB-361M2Gwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnHZTWM2OD12LkOzNVU{KM7:TR?=M{nyS3NCVkeHUh?=
NCI-H661M3L5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWnpO5J2UUN3ME20MlUxODl{IN88US=>MXnTRW5ITVJ?
EW-11NYj2[o5TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVK5eW1NUUN3ME20MlUzOjNzIN88US=>M1TOO3NCVkeHUh?=
BENNVrEOldVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkXWTWM2OD12LkWyPFE2KM7:TR?=Mn7WV2FPT0WU
BFTC-909NGHONoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmDQTWM2OD12LkW2Nlc2KM7:TR?=MWXTRW5ITVJ?
NCI-H2087NGO4cmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXrYSXJwUUN3ME20MlU5OTZ2IN88US=>NGnYUJpUSU6JRWK=
RVH-421Ml[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1HqSGlEPTB;ND62OlY6KM7:TR?=MlTsV2FPT0WU
P30-OHKMl7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY\0c|djUUN3ME20MlY5ODB6IN88US=>NWDuO2NkW0GQR1XS
NCI-H28Mm\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTRwOEG2OlEh|ryPMXLTRW5ITVJ?
ES6MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M37ySWlEPTB;ND64N|AyPiEQvF2=MmP1V2FPT0WU
769-PNHvTRpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVvJR|UxRTRwOEW5NlYh|ryPNVTBcphyW0GQR1XS
OE33M1jaT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGPBc5VKSzVyPUSuPFgyPjFizszNMV;TRW5ITVJ?
SW982NInoNnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTRwOUWwOlEh|ryPM3y2XHNCVkeHUh?=
A388NV;MdZJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\2dmlEPTB;NT6wNlk5OyEQvF2=M1vYT3NCVkeHUh?=
TI-73M{LY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTVwME[xPVQh|ryPMV;TRW5ITVJ?
HCT-116MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{TYUGlEPTB;NT6wPVg5QSEQvF2=NWG3TZJYW0GQR1XS
HuP-T3NWTn[HNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHuyeI5KSzVyPUWuNVg4ODlizszNNYK3fI14W0GQR1XS
G-402Mnr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn7QTWM2OD13LkG5OFE3KM7:TR?=NHPKZppUSU6JRWK=
NCI-H1792MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGTXZYVKSzVyPUWuNlQ3OjJizszNMVXTRW5ITVJ?
NCI-H209MkHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUT1NVlbUUN3ME21MlI2QTR{IN88US=>MmqyV2FPT0WU
NCI-H1650NHXFXIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NELDPHRKSzVyPUWuN|A3OzRizszNMoDZV2FPT0WU
LCLC-97TM1NFixOpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH7mTItKSzVyPUWuN|E5ODhizszNMnT4V2FPT0WU
S-117NHX6S4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYS1UldkUUN3ME21MlM3QTd4IN88US=>NFnlNGhUSU6JRWK=
GI-ME-NM2LORmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUTWd5VDUUN3ME21MlM6PjhzIN88US=>M{LaSHNCVkeHUh?=
NCI-H2122MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX7JR|UxRTVwNEmzPVch|ryPMm\BV2FPT0WU
NCI-H1793NHnMVlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRTVwNke1PVMh|ryPMXXTRW5ITVJ?
C2BBe1Ml7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGO5TWNKSzVyPUWuO|AxQDhizszNNE\1XVZUSU6JRWK=
TE-12M3nPVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYHjTFBsUUN3ME21MlgxPTV4IN88US=>MmjmV2FPT0WU
LCLC-103HMoDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MofhTWM2OD13LkmxO{DPxE1?M2PqSXNCVkeHUh?=
A673MorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnjXTWM2OD13LkmxPVMzKM7:TR?=NEDr[mpUSU6JRWK=
BB30-HNCNUnwV3lvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoD4TWM2OD13Lkm4N|Yh|ryPNInKPFBUSU6JRWK=
SF295MoXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXL6cWczUUN3ME22MlAxPDJ{IN88US=>NH2wXWJUSU6JRWK=
KU-19-19MkPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1;Ee2lEPTB;Nj6wNVc{OSEQvF2=M1frcXNCVkeHUh?=
CFPAC-1MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1jGeWlEPTB;Nj6wOFQ1OyEQvF2=NFuzTVJUSU6JRWK=
LoVoNIPoSmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXnCXWxtUUN3ME22MlA2ODZ|IN88US=>M1HydHNCVkeHUh?=
8505CMlLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWS3fZBSUUN3ME22MlA4PTd|IN88US=>NF3vSXNUSU6JRWK=
GMS-10M4H1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTZwMUWwNFIh|ryPM1nJfXNCVkeHUh?=
Ca9-22MlLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIfN[XpKSzVyPU[uNVY4OSEQvF2=NHPwWFBUSU6JRWK=
DOKM2ruc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX7u[4czUUN3ME22MlIzODd{IN88US=>MXjTRW5ITVJ?
FADUNIi5T4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{n0RWlEPTB;Nj6yOlA{QSEQvF2=NGDTW2RUSU6JRWK=
BxPC-3MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXfEfnRFUUN3ME22MlI4OzJizszNNGXzZmZUSU6JRWK=
CAL-33NHTyRmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml23TWM2OD14LkK5NlAyKM7:TR?=MUnTRW5ITVJ?
SHP-77NGOyepBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2fwXmlEPTB;Nj6zNVUyOiEQvF2=M3;qfnNCVkeHUh?=
LXF-289MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXfJR|UxRTZwM{O0OVUh|ryPMl7HV2FPT0WU
GB-1MlryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEjX[XdKSzVyPU[uN|gzKM7:TR?=NIrHWJRUSU6JRWK=
KS-1NHHKTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUDFdGx[UUN3ME22MlM5PDR5IN88US=>MojPV2FPT0WU
D-502MGNIrKXG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlfiTWM2OD14LkSyN|c3KM7:TR?=NXTEWmQ4W0GQR1XS
LAN-6NHfUT4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4r6R2lEPTB;Nj61NVAzOyEQvF2=MnHIV2FPT0WU
H-EMC-SSM1LXOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFGzdW9KSzVyPU[uOVYyPDdizszNNYXTNIcyW0GQR1XS
LC-2-adNHT1fIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEG1bnBKSzVyPU[uOlAxPzZizszNNFLCTYdUSU6JRWK=
NCI-H1693MmDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlLUTWM2OD14Lk[yNlE2KM7:TR?=MUPTRW5ITVJ?
SK-N-FINWDCe3c{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXO3NYdsUUN3ME22Mlc2ODR2IN88US=>NUG1NotRW0GQR1XS
D-423MGMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmrBTWM2OD14Lke2NVE4KM7:TR?=MW\TRW5ITVJ?
KNS-42NXvwWmViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Moq2TWM2OD14Lke4NVk4KM7:TR?=NHn1epJUSU6JRWK=
GCTNGS3VIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3P2VWlEPTB;Nj65N|gh|ryPNYrnVmp6W0GQR1XS
DSH1MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTdwME[zN{DPxE1?NY\QZ5RmW0GQR1XS
D-247MGNXnY[XhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHz6dItKSzVyPUeuNFc5QDFizszNNUntXGIzW0GQR1XS
NCI-SNU-5NI\ibo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1G1fmlEPTB;Nz6xPFM4OSEQvF2=NHTEWm5USU6JRWK=
TE-6MoXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUXJR|UxRTdwMkC2NFEh|ryPMYTTRW5ITVJ?
NOMO-1NWmwOGdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXWx[GtjUUN3ME23MlIzOTJ5IN88US=>M1TJVHNCVkeHUh?=
NB17M4TsOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGLTNVdKSzVyPUeuN|A{ODlizszNNYnCXIxiW0GQR1XS
EW-22Ml:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml3zTWM2OD15LkO0N|Q5KM7:TR?=NUe4bJFHW0GQR1XS
EW-13NXvxboQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3z2V2lEPTB;Nz6zOVE3OiEQvF2=MkHZV2FPT0WU
DOHH-2MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYLJR|UxRTdwNESwNkDPxE1?MoL2V2FPT0WU
TGBC1TKBMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFTSdmFKSzVyPUeuOFk5QTlizszNNHT0NGxUSU6JRWK=
GR-STNWfSRlNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFHKU3ZKSzVyPUeuOVI2QTRizszNNX;ZfHNYW0GQR1XS
KYSE-520NEPw[GRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEDrfHBKSzVyPUeuOVU2OTVizszNMlzVV2FPT0WU
CAPAN-1MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrXeXh{UUN3ME23MlU6PTFizszNM1nwNXNCVkeHUh?=
HCE-4NEG4WmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH3ad5lKSzVyPUeuOlIzPzlizszNMVzTRW5ITVJ?
MLMAMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVT4OXFjUUN3ME23MlYzQTV5IN88US=>MmrLV2FPT0WU
HT-144MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWDkeIluUUN3ME23MlY2OzZ6IN88US=>NWKwWY9IW0GQR1XS
KYSE-180MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoToTWM2OD15LkexNVY6KM7:TR?=MnzWV2FPT0WU
TE-5M17kOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoPXTWM2OD15Lkm1PVcyKM7:TR?=MWHTRW5ITVJ?
IGROV-1NHrvOGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NW\nc4NTUUN3ME23Mlk5PTVzIN88US=>MX7TRW5ITVJ?
NCI-H1581NUn2cHRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRThwMEGyJO69VQ>?NYezZotCW0GQR1XS
SW1990M4ThR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkfFTWM2OD16LkC0OlU6KM7:TR?=NHXaN2ZUSU6JRWK=
EFM-19MoHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEnFfVlKSzVyPUiuNFg2PDVizszNMkjkV2FPT0WU
OGR-1NFr5U4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml;zTWM2OD16LkSzNFI{KM7:TR?=MWXTRW5ITVJ?
U-118-MGNWTlNm1mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYDXR29IUUN3ME24MlQ{PDZ|IN88US=>MnrIV2FPT0WU
SK-OV-3NFX2NZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3i0emlEPTB;OD60Olc3PSEQvF2=NVHIZm5OW0GQR1XS
KNS-62NGm0O5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHH2WZFKSzVyPUiuOVE4PjFizszNMn\YV2FPT0WU
GOTOMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUT1XHpJUUN3ME24MlU4PjN3IN88US=>NWTMUXFQW0GQR1XS
8305CMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFXtXXVKSzVyPUiuO|A1QDRizszNMWfTRW5ITVJ?
RPMI-2650NGfLZXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVjJR|UxRThwN{G5OVUh|ryPM17wfXNCVkeHUh?=
NEC8M33WfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXTJR|UxRThwN{SzNFch|ryPM1W1S3NCVkeHUh?=
KYSE-450NY\4ZYF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1vCRmlEPTB;OD64OlU1QCEQvF2=NG\tNpVUSU6JRWK=
RMG-INGTlNWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF;GbHBKSzVyPUmuNVQxPThizszNMmLuV2FPT0WU
CAKI-1M3vVRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M13yUWlEPTB;OT6zNVk4QSEQvF2=M4TqXnNCVkeHUh?=
KYSE-510MnXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2qxXWlEPTB;OT6zOVc4QCEQvF2=NFXGWGVUSU6JRWK=
A4-FukNESze3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn76TWM2OD17LkO2O|AyKM7:TR?=NVz2VIRbW0GQR1XS
AN3-CANWjtUnpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1XPPWlEPTB;OT60OVQ1PCEQvF2=MYPTRW5ITVJ?
SK-N-DZMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlzZTWM2OD17LkeyPFQ6KM7:TR?=MVHTRW5ITVJ?
HSC-2M4jVN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3jzTmlEPTB;OT63OlYzQSEQvF2=NVz2OFFWW0GQR1XS
EW-1NGmwTWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\xTWM2OD17Lke5N|Y6KM7:TR?=MmXLV2FPT0WU
D-566MGMnrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXLjZolIUUN3ME25Mlg{PjZ2IN88US=>NVy1eXI4W0GQR1XS
COLO-792M4jWOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4TVXWlEPTB;OT65PFc1PiEQvF2=NX;XendVW0GQR1XS
TE-10NUPvOZFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{TpdmlEPTB;MUCuNFM6PiEQvF2=MkD0V2FPT0WU
NCI-H650NF2xPHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmXRTWM2OD1zMD60Nlg3KM7:TR?=MoHZV2FPT0WU
U-266NYj5WG9RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIezZVJKSzVyPUGwMlQ2PSEQvF2=MnrTV2FPT0WU
Detroit562MknES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3LCfGlEPTB;MUGuNFUyPSEQvF2=NWnCXHlMW0GQR1XS
NH-12NUDBeZFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWnNUZdqUUN3ME2xNU4yPDR4IN88US=>M4jkS3NCVkeHUh?=
CO-314NHrTZpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3qyUmlEPTB;MUGuNlg1OiEQvF2=NGLBUFFUSU6JRWK=
IST-MEL1NW\QUnhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1rwbmlEPTB;MUGuOVMzOyEQvF2=M336OnNCVkeHUh?=
KNS-81-FDMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4HRUmlEPTB;MUGuOVUzPyEQvF2=MV7TRW5ITVJ?
SW1463NWqyT3NST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1L0NGlEPTB;MUGuOVk5QSEQvF2=NFjWc2RUSU6JRWK=
NCI-H23NEnpV4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTFzLk[1OVIh|ryPMoDyV2FPT0WU
SK-MEL-2NWXrNXpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUDJR|UxRTFzLkexPVch|ryPM2TCRnNCVkeHUh?=
NB13M4q0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRTF{LkG0PVUh|ryPMVfTRW5ITVJ?
DaoyNHjmSoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVjJR|UxRTF{LkK4OVYh|ryPNVq2VXR3W0GQR1XS
NCI-H1623MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIrxOG1KSzVyPUGyMlM5ODFizszNM1flT3NCVkeHUh?=
NMC-G1MlXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NViyXm5YUUN3ME2xNk44OTdizszNMmHYV2FPT0WU
DK-MGNVP3R3RrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYjIUJVRUUN3ME2xNk46PDh{IN88US=>NGPYdopUSU6JRWK=
TCCSUPNXu1PIhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXjBRohwUUN3ME2xN{4yOjh2IN88US=>NVnyZXlvW0GQR1XS
SCC-15M3fRXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkPtTWM2OD1zMz6yOlUyKM7:TR?=MX3TRW5ITVJ?
NOS-1NET6W3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIrGXGtKSzVyPUGzMlI5QTNizszNMn7rV2FPT0WU
RH-1MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYHJR|UxRTF|LkOwN|ch|ryPNXXDT2JvW0GQR1XS
SK-MEL-3MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1jGXmlEPTB;MUOuN|czQCEQvF2=NVfJXIdiW0GQR1XS
NB5NGflZ29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkDVTWM2OD1zMz60NFY4KM7:TR?=NF;WTVZUSU6JRWK=
SNU-387NW\2UFNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVrJR|UxRTF|LkWwO|Ih|ryPNHPOcYhUSU6JRWK=
CAL-120M1PTS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn;4TWM2OD1zMz62O|E5KM7:TR?=MnrMV2FPT0WU
Mo-TNFrMVGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX\JR|UxRTF|LkewO{DPxE1?MWTTRW5ITVJ?
LNCaP-Clone-FGCNGTaWVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2jCVWlEPTB;MUOuO|k6OiEQvF2=MW\TRW5ITVJ?
CANNV;hbWpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTF2LkCyPFgh|ryPNIjLN2VUSU6JRWK=
SK-MEL-30NH;kN5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGO2co5KSzVyPUG0MlA3OyEQvF2=M{\0UXNCVkeHUh?=
COLO-678M2PuV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUnEeJZuUUN3ME2xOE4xQDJ{IN88US=>NXy3N4ViW0GQR1XS
SCC-9M4n3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mo\YTWM2OD1zND6xNFIyKM7:TR?=NHW0PW1USU6JRWK=
KINGS-1MmHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M33hW2lEPTB;MUSuNVQxOiEQvF2=M{D6TXNCVkeHUh?=
SL-513M1PQc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWS2R|R2UUN3ME2xOE4yQDdizszNNWHqbVMyW0GQR1XS
HLEM{X1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnPDTWM2OD1zND6zPFUzKM7:TR?=MY\TRW5ITVJ?
SW1573Mlu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NW\hdWE2UUN3ME2xOE41PDN3IN88US=>M3GxcnNCVkeHUh?=
KYSE-140MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NULx[Vl5UUN3ME2xOE43OzJ5IN88US=>NXrWd441W0GQR1XS
SK-PN-DWNUPS[GhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3vyb2lEPTB;MUSuPFAxOSEQvF2=M2HnRnNCVkeHUh?=
A253M3XUVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NELhZWZKSzVyPUG1MlA3OjVizszNMYDTRW5ITVJ?
CAL-12TMknSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHLFZnBKSzVyPUG1MlQ3PjJizszNMYHTRW5ITVJ?
COLO-679MmLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MonUTWM2OD1zNT63Olg{KM7:TR?=MkTaV2FPT0WU
UACC-257NXXJZ5Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{PYWGlEPTB;MU[uNVIxOSEQvF2=NUfNZXByW0GQR1XS
U-87-MGMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MU\JR|UxRTF4LkO1NlMh|ryPNXrOUlY5W0GQR1XS
HCC1806NGSxRVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUSwOVRNUUN3ME2xOk44ODdzIN88US=>MUnTRW5ITVJ?
NCI-H2170NW\yeYhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MofsTWM2OD1zNz6yOFQ5KM7:TR?=MVzTRW5ITVJ?
AGSM1H1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{fPc2lEPTB;MUeuN|gxQCEQvF2=MWrTRW5ITVJ?
MEL-HONXjvWFBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTF5Lke1NFMh|ryPNYP1XpRlW0GQR1XS
SW48MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTF5Lke3NVYh|ryPMXjTRW5ITVJ?
HuP-T4M4H0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYPLfWFSUUN3ME2xPE4xOjB4IN88US=>NID6[XhUSU6JRWK=
NCI-H720MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnnTTWM2OD1zOD6xOFAzKM7:TR?=MXnTRW5ITVJ?
RCC10RGBMmDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1;VfGlEPTB;MUiuNVY6PyEQvF2=MVnTRW5ITVJ?
HD-MY-ZMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVHJR|UxRTF6LkKyOVQh|ryPNYPIU2M1W0GQR1XS
A427MmC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV3UcGw6UUN3ME2xPE42ODl2IN88US=>M2r2WnNCVkeHUh?=
HCC2998M13FPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NITieFlKSzVyPUG4MlYxPTFizszNMmjQV2FPT0WU
EPLC-272HMmm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkfQTWM2OD1zOT6wOFM1KM7:TR?=M{Dq[XNCVkeHUh?=
C32NIrKXnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoHtTWM2OD1zOT6wOFUh|ryPNVHVcFh{W0GQR1XS
UMC-11NFHMTlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXHpcHhJUUN3ME2xPU4zOTJ|IN88US=>NWWwTmlnW0GQR1XS
CaR-1MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{fiSmlEPTB;MUmuOlgxPCEQvF2=MlXJV2FPT0WU
KYSE-410NUjwR21zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3XIUWlEPTB;MUmuPVE{QSEQvF2=M4[yNXNCVkeHUh?=
HuCCT1MkL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MorvTWM2OD1{MD62Nlk1KM7:TR?=MkPRV2FPT0WU
LB996-RCCM2XUfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFPlZpZKSzVyPUKwMlcyPjhizszNMX7TRW5ITVJ?
KYSE-70MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGTHN3BKSzVyPUKwMlgxPTlizszNNHPHfWRUSU6JRWK=
CAL-72NED6c3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3m4VWlEPTB;MkCuPVE2KM7:TR?=NYjOe4t5W0GQR1XS
Capan-2MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoLPTWM2OD1{MT6wOFE{KM7:TR?=NH;tcVJUSU6JRWK=
PANC-08-13NGfDXVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWnjSmJ1UUN3ME2yNU4zPTF3IN88US=>M3nIb3NCVkeHUh?=
SBC-1NU\5d|RST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIfUWXFKSzVyPUKxMlMxQDFizszNMWLTRW5ITVJ?
MFM-223NGD2W4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTJzLkOzOFIh|ryPM2noXnNCVkeHUh?=
BB49-HNCNHrPZppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnLZTWM2OD1{MT61O|E3KM7:TR?=M2jTZnNCVkeHUh?=
SH-4NXTCU29CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRTJzLk[2NVgh|ryPNV7lRpF7W0GQR1XS
HuO9NV;5OGNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUHUbmJKUUN3ME2yNU46QDJ3IN88US=>MonoV2FPT0WU
AM-38NHzPdpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHrxd45KSzVyPUKyMlA1QDVizszNMlTtV2FPT0WU
A431NHqzU2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mo\QTWM2OD1{Mz6yNVE6KM7:TR?=MYDTRW5ITVJ?
YAPCNYLBVWpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYXPe3dSUUN3ME2yN{4zPjVzIN88US=>NIDlNoJUSU6JRWK=
LU-139M2rDVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWjOflAxUUN3ME2yN{41QDB7IN88US=>NEXQOHlUSU6JRWK=
HEC-1MnWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGDVWoRKSzVyPUKzMlQ6OzdizszNMVjTRW5ITVJ?
SCC-25M4HsR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlPzTWM2OD1{ND6zNFA3KM7:TR?=NGC5eFNUSU6JRWK=
HT-29NH\vV3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTJ2LkO4NlMh|ryPNH7MW4NUSU6JRWK=
PC-14NUjNVlMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHLFdmRKSzVyPUK0MlY2PzFizszNMUfTRW5ITVJ?
Calu-6MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH3EbFZKSzVyPUK1MlUxPzFizszNNGT6T4JUSU6JRWK=
SJRH30NIm3PW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUGwW255UUN3ME2yOU43PDl4IN88US=>M{LI[nNCVkeHUh?=
ChaGo-K-1M2fVU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3W4N2lEPTB;Mk[uNVYzQSEQvF2=MWDTRW5ITVJ?
IA-LMMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm\ITWM2OD1{Nj6zOlQ2KM7:TR?=NWHOVYJWW0GQR1XS
GP5dNHP3SnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4GwV2lEPTB;Mk[uOFQ6OSEQvF2=NIiyc4lUSU6JRWK=
NCI-H2291NUTTWZNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlH5TWM2OD1{Nj62OVQyKM7:TR?=NHv0cFVUSU6JRWK=
BALL-1M{Gwcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3ztSWlEPTB;Mk[uPVM6PyEQvF2=MYjTRW5ITVJ?
HCC1954NHXsOWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV21WI1OUUN3ME2yOk46QDB6IN88US=>M33PXHNCVkeHUh?=
NCI-H2452MoCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIfjTGJKSzVyPUK3MlQyPjNizszNM2C3dXNCVkeHUh?=
LU-99ANX\OPZVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWXJR|UxRTJ5LkW1PFIh|ryPNX3NWJl1W0GQR1XS
NTERA-S-cl-D1MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWnJR|UxRTJ5LkeyPVkh|ryPNWLpd3ZVW0GQR1XS
PANC-10-05MnXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4DQPWlEPTB;MkeuO|c4PSEQvF2=M3LoZ3NCVkeHUh?=
NCI-H2405NF6yNHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV74WmEzUUN3ME2yO{46Ozh5IN88US=>MV\TRW5ITVJ?
MDA-MB-415NXjpdnhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRTJ6LkSxN|ch|ryPMYDTRW5ITVJ?
NCI-H2342NWXJdHVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml\UTWM2OD1{OD61NlgyKM7:TR?=M3jCVHNCVkeHUh?=
TGBC24TKBNEDjPG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTJ6LkexNVch|ryPMlzGV2FPT0WU
LU-134-AMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW\hOHNvUUN3ME2yPE46OjZzIN88US=>M1iyWnNCVkeHUh?=
SCC-4MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4XpOWlEPTB;M{GuNFQ6PCEQvF2=M3jDbXNCVkeHUh?=
Saos-2M{nrUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGHZXnZKSzVyPUOxMlk{ODZizszNMoO3V2FPT0WU
RERF-LC-MSMl\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlexTWM2OD1|Mj64NlMyKM7:TR?=NWrSNIFXW0GQR1XS
M14Mk\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX3MWFQ4UUN3ME2zNk46PzZ2IN88US=>Mlz3V2FPT0WU
HPAF-IINX3GR41UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoP3TWM2OD1|Mz61NFEyKM7:TR?=MULTRW5ITVJ?
NCI-H1755Mle2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{OwVWlEPTB;M{SuN|MxPSEQvF2=MlXGV2FPT0WU
D-392MGMlzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1PDTWlEPTB;M{WuPFY4PCEQvF2=MVvTRW5ITVJ?
A704NHLmfFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYHUfZdxUUN3ME2zOk4xPDJ5IN88US=>NHTPblVUSU6JRWK=
CP50-MEL-BMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUXJR|UxRTN4LkG5NVEh|ryPNETkPIxUSU6JRWK=
EW-18NUTw[pVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXrrc49xUUN3ME2zOk41PTJizszNM1;GOHNCVkeHUh?=
WM-115M4PCRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFjiN4JKSzVyPUO2MlgxQTlizszNMXPTRW5ITVJ?
LU-65NI\oZ5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3:1ZWlEPTB;M{euNVQyPyEQvF2=M4PjXnNCVkeHUh?=
NCI-H1563M{LZfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4S2W2lEPTB;M{euNlQ5PCEQvF2=M2DxTHNCVkeHUh?=
DBTRG-05MGM3nhNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIP3cZRKSzVyPUO4MlA3QTFizszNM13MZXNCVkeHUh?=
NCI-H630M2XXVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkjVTWM2OD1|OD60O|E1KM7:TR?=MYLTRW5ITVJ?
NCI-H1155MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXHaeWZvUUN3ME2zPU4zPDJizszNNFru[3VUSU6JRWK=
OVACR-3MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX[1[oRrUUN3ME2zPU46OTl3IN88US=>NGXGRYNUSU6JRWK=
OAW-42NFXwVZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHv3OFdKSzVyPUSwMlQzPThizszNNV;1dG5LW0GQR1XS
JVM-2NFHxVIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTRzLkK0NVUh|ryPM4PSSXNCVkeHUh?=
C3AMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE\HTXdKSzVyPUSxMlM1PDdizszNNFHkNJdUSU6JRWK=
HT55MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVjzNmo2UUN3ME20Nk4zQDRzIN88US=>NX7lW2o5W0GQR1XS
OVCAR-4MnvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFPpWlJKSzVyPUSyMlI6PzRizszNNV3NfIxxW0GQR1XS
MEG-01MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmnHTWM2OD12Mj60OlE3KM7:TR?=MYXTRW5ITVJ?
NCI-H82M33KTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M17WVmlEPTB;NEOuPVg6OiEQvF2=NWH3U45oW0GQR1XS
JEG-3MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1LhcmlEPTB;NESuPVQ4KM7:TR?=NWG1UXRYW0GQR1XS
BPH-1MmG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTR4LkO5PVgh|ryPMorsV2FPT0WU
MPP-89NFvUcoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFfUbpJKSzVyPUS3MlI5QThizszNMXzTRW5ITVJ?
ALL-POMWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MorXTWM2OD12Nz60NVg5KM7:TR?=NVjOdVh7W0GQR1XS
HTNVTxN5BzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MULJR|UxRTR5LkS5NkDPxE1?Mo\ZV2FPT0WU
NCI-H2347NULwOmNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTR6LkC3NVUh|ryPMnv1V2FPT0WU
A2780M2\D[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTR7LkSyNlgh|ryPM4i2O3NCVkeHUh?=
KARPAS-299MkPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX;JR|UxRTR7LkWxNVkh|ryPM4qxcXNCVkeHUh?=
NCI-H1651MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3f2d2lEPTB;NEmuPFgzOSEQvF2=MVTTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]
Features Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).

Protocol(Only for Reference)

Kinase Assay: [1]

Cdk Assays A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.

Cell Assay: [1]

Cell lines Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
Concentrations 0.01-1 μM
Incubation Time 24 hours
Method Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.

Animal Study: [1]

Animal Models Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
Formulation Dissolved in sodium lactate buffer (50 mM, pH 4.0)
Dosages 0-150 mg/kg
Administration Given by gavage

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Fry DW, et al. Mol Cancer Ther, 2004, 3(11), 1427-1438.

[2] Menu E, et al. Cancer Res, 2008, 68(14), 5519-5523.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02730429 Not yet recruiting Endometrial Cancer Nordic Society for Gynaecologic Oncology|ENGOT|GCIG August 2016 Phase 2
NCT02778685 Not yet recruiting Estrogen Receptor Positive|HER2/Neu Negative|Postmenopausal|Recurrent Breast Carcinoma|Stage IV Breast Cancer City of Hope Medical Center|National Cancer Institute (NCI) July 2016 Phase 2
NCT02738866 Not yet recruiting Metastatic Breast Cancer Sidney Kimmel Comprehensive Cancer Center|Pfizer July 2016 Phase 2
NCT02668666 Recruiting Hormone Receptor Positive Malignant Neoplasm of Breast|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Estrogen Receptor Positive Brea  ...more Hormone Receptor Positive Malignant Neoplasm of Breast|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Estrogen Receptor Positive Breast Cancer|Progesterone Receptor Positive Tumor|Metastatic Breast Cancer Oana Danciu, MD|Pfizer|Hoosier Cancer Research Network|Bi  ...more Oana Danciu, MD|Pfizer|Hoosier Cancer Research Network|Big Ten Cancer Research Consortium June 2016 Phase 2
NCT02806050 Not yet recruiting Breast Cancer University Medical Center Groningen June 2016 Phase 2

view more

Chemical Information

Download Palbociclib (PD-0332991) HCl SDF
Molecular Weight (MW) 483.99
Formula

C24H29N7O2.HCl

CAS No. 827022-32-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 3 mg/mL warming (6.19 mM)
Water 30 mg/mL (61.98 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo Saline 20 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 6-acetyl-8-cyclopentyl-5-methyl-2-(5-(piperazin-1-yl)pyridin-2-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one hydrochloride

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related CDK Products

  • SU9516

    SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.

  • Ro-3306

    RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

  • Purvalanol A

    Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively.

  • Palbociclib (PD0332991) Isethionate

    Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

    Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.

  • Dinaciclib (SCH727965)

    Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Phase 3.

  • Flavopiridol (Alvocidib) HCl

    Flavopiridol HCl competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.

  • Roscovitine (Seliciclib,CYC202)

    Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.

  • abemaciclib (LY2835219)

    LY2835219 is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.

  • Ribociclib (LEE011)

    Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor. Phase 3.

  • SNS-032 (BMS-387032)

    SNS-032 (BMS-387032) has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM in cell-free assays and is 10- and 20-fold selective over CDK1/CDK4. It is also found to be sensitive to CDK7/9 with IC50 of 62 nM/4 nM, with little effect on CDK6. Phase 1.

Recently Viewed Items

Tags: buy Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl supplier | purchase Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl cost | Palbociclib (PD-0332991) HCl manufacturer | order Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us